By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.

OK

Five Essentials from CTFN this Week

AET/CVS
On the sidelines of the Connecticut Insurance Department Form A hearing regarding CVS Health’s $69 billion acquisition of Aetna, CVS general counsel Tom Moriarty told CTFN the parties are making good progress with the pending antitrust review with the Department of Justice, and “are almost there.”

SHPG/4502:JP
Chances that the group of Takeda minority shareholders opposing the Japanese drug maker’s planned acquisition of rival Shire will succeed in blocking the deal appear to be low, local sources told CTFN.

NXTM/FRE:GR
The review by the U.S. Federal Trade Commission of the acquisition of NxStage by Fresenius is on track and moving forward, according to a source familiar with the matter. In addition to the sale of NxStage’s bloodlines unit, which was announced on July 19, and is subject to FTC approval of the NxStage/Fresenius merger, it now appears the deal will also need a divestiture of assets in the peritoneal area, according to the source.

FOXA/DIS
The state of play meeting between the European Commission and Disney for the U.S. company’s acquisition of Twenty-First Century Fox is expected in the coming days, competition sources told CTFN.

LINU:GR/PX
A person close to the matter told CTFN, “The U.S. Federal Trade Commission and Korea have been focused on laser gases for the past two weeks,” adding, “This is not surprising to the parties, and although frustrating, it will not negate the deal. The market (laser gases) in the scheme of things is not significant.”

To Keep Reading, Request a Trial
Stephen Velgot

Stephen Velgot

Stephen Velgot has more than twenty years experience as a research analyst. He most recently started an event driven research product at Renaissance Macro Research after covering risk arbitrage at ICAP and event driven situations at Susquehanna and Cathay Financial. Stephen has an MBA in Finance from New York University and a BS in Operations Research from Cornell University.

X

Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.